Arnold & Porter‘s competition practice is well-versed in advising clients in the life sciences and technology sectors, particularly with regard to merger control matters. Practice head Niels Ersbøll has extensive merger control experience, regularly navigating multi-jurisdictional clearance requirements within the life sciences and pharmaceutical sectors. Axel Gutermuth stands out for his expertise in international merger control filings. The team is supported by merger control, abuse of dominance, and cartel expert Lazarinka Naydenova.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Testimonials
Collated independently by Legal 500 research team.
- ‘Extremely knowledgeable, strategic in their thinking, very well connected with regulators, with a particular focus and understanding of the pharma and life science sectors.'
- 'They are responsive, very pragmatic and easy to collaborate with.’
- ‘Niels Ersbøll is notable for his client care, responsiveness, strategic thinking and pragmatic approach to matters.’
- ‘The team is well-versed in EU and global competition issues across jurisdictions. They also take a very thoughtful approach with respect to strategy for cross-border issues.’
- ‘Niels Ersbøll: exceptional legal counsel with a deep understanding of how competition laws apply to pharmaceutical companies. Very fast, efficient and pragmatic advice with a great focus on the commercial needs of our business.’
- ‘Very experienced and skilled team.'
Key clients
- Novo Nordisk
- Curium Pharma
- Boston Scientific Corporation
- Pfizer
- Gilead
- Argenx
- Takeda
- Galderma
- Lundbeck
- Embecta
- The International Federation of Pharmaceutical Manufacturers and Associations
- Palo Alto Networks
Work highlights
Advising Palo Alto Networks its $25bn acquisition of CyberArk.
Advised Curium Pharma on its successful acquisition of Monrol.
Advised Novo Nordisk on its pending $16.5bn acquisition of CDMO Catalent.
Practice head
Niels Ersbøll
Other key lawyers
Axel Gutermuth; Lazarinka Naydenova